# A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

> **NCT07754799** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 320 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Liposome Mitoxantrone
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07754799
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754799, "A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07754799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*